Quick Answer
Bolt Biotherapeutics, Inc. reported Stockholders Equity of $26.51 million for the year ending 2025.
- Bolt Biotherapeutics, Inc. showed a decrease of -53.7% in Stockholders Equity from 2024 to 2025.
- This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$54.23 million | Q2 2020: -$65.04 million | Q3 2020: -$74.59 million | Q1 2021: $303.25 million | Q2 2021: $295.90 million | Q3 2021: $274.91 million | Q1 2022: $228.39 million | Q2 2022: $207.97 million | Q3 2022: $188.45 million | Q1 2023: $157.69 million | Q2 2023: $142.13 million | Q3 2023: $128.26 million | Q1 2024: $104.16 million | Q2 2024: $85.86 million | Q3 2024: $72.03 million | Q1 2025: $46.81 million | Q2 2025: $38.84 million | Q3 2025: $32.10 million.
- Over the full 7 years of available data (2019 to 2025), Bolt Biotherapeutics, Inc.'s Stockholders Equity has grown by 157.8%.
- Historical annual values: Fiscal year 2025: $26.51 million | Fiscal year 2024: $57.20 million | Fiscal year 2023: $112.74 million | Fiscal year 2022: $171.51 million | Fiscal year 2021: $250.12 million | Fiscal year 2020: -$104.95 million | Fiscal year 2019: -$45.85 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: